Table 3.
Selection of clinical trials for small molecule approaches to EBV-associated malignancies
| NIH Clinical Trials Identifier | Compound | Class | application | Status as of January, 2022 |
|---|---|---|---|---|
| NCT05011058 | Nanatinostat | Class I HDAC inhibitor | In combination with Valganciclovir in patients with relapsed/refractory EBV-positive lymphomas, including: EBV- associated lymphoproliferative disease; PTLD, Non-Hodgkin lymphoma, extranodal NK/T, DLBC, Hodgkin lymphoma, PTCL | Recruiting (Phase II) |
| NCT04925544 | VK-2019 | EBNA1 inhibitor | Advanced NPC | Recruiting (Phase II) |
| NCT02670616 | Ibrutinib | BTK inhibitor | In combination with Rituximab-CHOP for diffuse large B-cell lymphoma | Completed (Phase II) |
| NCT01094405 | HQK-1004 | HDAC inhibitor | In combination with Valganciclovir for relapsed/refractory EBV lymphoid malignancies and lymphoproliferative disorders | Completed (Phase II) |
References Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Léonard P, Moreels A, Haumont M, Bollen A, Smets F, Denis M. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis. 2007 Dec 15;196(12):1749–53. doi: 10.1086/523813.
Edwin P. Hui, Graham S. Taylor, Hui Jia, Brigette B.Y. Ma, Stephen L. Chan, Rosalie Ho, Wai-Lap Wong, Steven Wilson, Benjamin F. Johnson, Ceri Edwards, Deborah D. Stocken, Alan B. Rickinson, Neil M. Steven and Anthony T.C. Chan Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein–Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients. Cancer Res. 2013. PMID: 23348421
Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P, Perales MA, Papadopoulos E, Sauter C, Castro-Malaspina H, Boulad F, Curran KJ, Giralt S, Gyurkocza B, Hsu KC, Jakubowski A, Hanash AM, Kernan NA, Kobos R, Koehne G, Landau H, Ponce D, Spitzer B, Young JW, Behr G, Dunphy M, Haque S, Teruya-Feldstein J, Arcila M, Moung C, Hsu S, Hasan A, O’Reilly RJ. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020 Feb 3;130(2):733–747. doi: 10.1172/JCI121127.